DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Takes $106,000 Position in DaVita Inc. (NYSE:DVA)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in shares of DaVita Inc. (NYSE:DVA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 708 shares of the company’s stock, valued at approximately $106,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DVA. Epoch Investment Partners Inc. acquired a new position in shares of DaVita in the fourth quarter worth about $55,100,000. Invesco Ltd. raised its holdings in DaVita by 20.9% in the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company’s stock worth $237,716,000 after purchasing an additional 275,284 shares during the period. Amundi boosted its position in DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after purchasing an additional 240,126 shares in the last quarter. Bridgewater Associates LP grew its holdings in DaVita by 298.4% in the fourth quarter. Bridgewater Associates LP now owns 239,970 shares of the company’s stock valued at $35,888,000 after purchasing an additional 179,744 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ increased its position in shares of DaVita by 256.8% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company’s stock valued at $24,301,000 after buying an additional 116,758 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Trading Up 0.4%

Shares of DVA opened at $144.29 on Tuesday. DaVita Inc. has a 52-week low of $131.44 and a 52-week high of $179.60. The stock has a market cap of $11.09 billion, a PE ratio of 13.43, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. The firm’s fifty day moving average is $145.93 and its two-hundred day moving average is $153.74. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.25. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The company had revenue of $3.22 billion during the quarter, compared to analysts’ expectations of $3.22 billion. During the same quarter in the prior year, the company earned $2.26 EPS. DaVita’s revenue was up 5.0% compared to the same quarter last year. Research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DVA has been the topic of a number of recent analyst reports. StockNews.com upgraded DaVita from a “hold” rating to a “buy” rating in a research report on Friday, April 25th. Cowen restated a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research report on Friday, February 21st. Finally, Barclays boosted their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.